Pixantrone is less cardiotoxic and is similarly effective to mitoxantrone (MTX) as an antineoplastic drug. In our study, pixantrone reduced the severity of acute and decreased the relapse rate of chronic relapsing experimental allergic encephalomyelitis (EAE) in rats. A marked and long-lasting decrease in CD3+, CD4+, CD8+ and CD45RA+ blood cells and reduced anti-MBP titers were observed with both pixantrone and MTX. In vitro mitogen- and antigen-induced T-cell proliferation tests of human and rodents cells evidenced that pixantrone was effective at concentrations which can be effectively obtained after i.v. administration in humans. Cardiotoxicity was present only in MTX-treated rats. The effectiveness and the favorable safety profile makes pixantrone a most promising immunosuppressant agent for clinical use in multiple sclerosis (MS).

Cavaletti, G., Cavalletti, E., Crippa, L., Di Luccio, E., Oggioni, N., Mazzanti, B., et al. (2004). Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis. JOURNAL OF NEUROIMMUNOLOGY, 151(1-2), 55-65 [10.1016/j.jneuroim.2004.02.008].

Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis

CAVALETTI, GUIDO ANGELO;OGGIONI, NORBERTO;RIGOLIO, ROBERTA;ZOIA, CHIARA PAOLA;TREDICI, GIOVANNI;
2004

Abstract

Pixantrone is less cardiotoxic and is similarly effective to mitoxantrone (MTX) as an antineoplastic drug. In our study, pixantrone reduced the severity of acute and decreased the relapse rate of chronic relapsing experimental allergic encephalomyelitis (EAE) in rats. A marked and long-lasting decrease in CD3+, CD4+, CD8+ and CD45RA+ blood cells and reduced anti-MBP titers were observed with both pixantrone and MTX. In vitro mitogen- and antigen-induced T-cell proliferation tests of human and rodents cells evidenced that pixantrone was effective at concentrations which can be effectively obtained after i.v. administration in humans. Cardiotoxicity was present only in MTX-treated rats. The effectiveness and the favorable safety profile makes pixantrone a most promising immunosuppressant agent for clinical use in multiple sclerosis (MS).
Articolo in rivista - Articolo scientifico
Cells, Cultured; Encephalomyelitis, Autoimmune, Experimental; Female; Rats; Animals; Immunosuppressive Agents; Lymphocyte Count; T-Lymphocytes; Humans; Isoquinolines; Acute Disease; Chronic Disease; Mitoxantrone; Cell Division
English
55
65
Cavaletti, G., Cavalletti, E., Crippa, L., Di Luccio, E., Oggioni, N., Mazzanti, B., et al. (2004). Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis. JOURNAL OF NEUROIMMUNOLOGY, 151(1-2), 55-65 [10.1016/j.jneuroim.2004.02.008].
Cavaletti, G; Cavalletti, E; Crippa, L; Di Luccio, E; Oggioni, N; Mazzanti, B; Biagioli, T; Sala, F; Sala, V; Frigo, M; Rota, S; Tagliabue, E; Stanzani, L; Galbiati, S; Rigolio, R; Zoia, C; Tredici, G; Perseghin, P; Dassi, M; Riccio, P; Lolli, F
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/20321
Citazioni
  • Scopus 32
  • ???jsp.display-item.citation.isi??? 29
Social impact